Lupus Nephritis - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Lupus Nephritis - Pipeline Review, H1 2016', provides an overview of the Lupus Nephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Lupus Nephritis - The report reviews pipeline therapeutics for Lupus Nephritis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Lupus Nephritis therapeutics and enlists all their major and minor projects - The report assesses Lupus Nephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Lupus Nephritis Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Lupus Nephritis Overview 9 Therapeutics Development 10 Pipeline Products for Lupus Nephritis - Overview 10 Pipeline Products for Lupus Nephritis - Comparative Analysis 11 Lupus Nephritis - Therapeutics under Development by Companies 12 Lupus Nephritis - Therapeutics under Investigation by Universities/Institutes 13 Lupus Nephritis - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Lupus Nephritis - Products under Development by Companies 17 Lupus Nephritis - Products under Investigation by Universities/Institutes 18 Lupus Nephritis - Companies Involved in Therapeutics Development 19 AbbVie Inc. 19 Asahi Kasei Pharma Corp. 20 Astellas Pharma Inc. 21 Azano Pharmaceuticals Inc. 22 Boehringer Ingelheim GmbH 23 Bristol-Myers Squibb Company 24 Deltanoid Pharmaceuticals Inc. 25 F. Hoffmann-La Roche Ltd. 26 FibroStatin SL 27 GlaxoSmithKline Plc 28 HanAll Biopharma Co., Ltd. 29 Invion Limited 30 Kineta, Inc. 31 MedImmune, LLC 32 Omeros Corporation 33 Takeda Pharmaceutical Company Limited 34 Zyrnat Biotherapeutics SL 35 Lupus Nephritis - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Target 37 Assessment by Mechanism of Action 39 Assessment by Route of Administration 41 Assessment by Molecule Type 43 Drug Profiles 45 abatacept - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 anifrolumab - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 belimumab - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 BI-655064 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 BMS-986147 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 dalazatide - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 DP-001 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 FSMAB-26 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 HL-161 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 INV-103 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 ixazomib citrate - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 mizoribine - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Monoclonal Antibody for Lupus Nephritis - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 obinutuzumab - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 OMS-721 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 P-Dex - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 RO-5461111 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Stem Cell Therapy for Autoimmune Diseases - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 venetoclax - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 voclosporin - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Y-175L - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 ZY-11 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Lupus Nephritis - Recent Pipeline Updates 90 Lupus Nephritis - Dormant Projects 124 Lupus Nephritis - Discontinued Products 126 Lupus Nephritis - Product Development Milestones 127 Featured News & Press Releases 127 Mar 29, 2016: Aurinia Announces Result from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis - Study to Continue as Planned 127 Mar 02, 2016: Aurina Receives FDA Fast Track Designation for Voclosporin for the Treatment of Lupus Nephritis 127 Feb 08, 2016: Aurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis 128 Feb 02, 2016: Deltanoid Pharmaceuticals Announces Appointment of Douglas Jermasek as Chief Executive Officer 128 Jan 19, 2016: Aurinia Announces Completion of Patient Enrollment in Its Phase 2B AURA-LV Study in Lupus Nephritis 129 Dec 03, 2015: Ocata's Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis 130 Nov 24, 2015: Aurinia Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis - Study to Continue as Planned 130 Nov 10, 2015: Kineta, Seattle Children's Research Institute Present New Data Demonstrating Positive, Predictive Responses to Dalazatide In Lupus 131 Aug 24, 2015: Ocata Therapeutics Receives SBIR Grant from NIH to Develop Proprietary Hemangio-derived Mesenchymal Cell Therapy for Lupus Nephritis 132 Jun 17, 2015: ACT Research Suggests Role for Dalazatide in Blocking T Cells from Patients with Lupus 132 Appendix 134 Methodology 134 Coverage 134 Secondary Research 134 Primary Research 134 Expert Panel Validation 134 Contact Us 134 Disclaimer 135
List of Tables
Number of Products under Development for Lupus Nephritis, H1 2016 10 Number of Products under Development for Lupus Nephritis - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Investigation by Universities/Institutes, H1 2016 18 Lupus Nephritis - Pipeline by AbbVie Inc., H1 2016 19 Lupus Nephritis - Pipeline by Asahi Kasei Pharma Corp., H1 2016 20 Lupus Nephritis - Pipeline by Astellas Pharma Inc., H1 2016 21 Lupus Nephritis - Pipeline by Azano Pharmaceuticals Inc., H1 2016 22 Lupus Nephritis - Pipeline by Boehringer Ingelheim GmbH, H1 2016 23 Lupus Nephritis - Pipeline by Bristol-Myers Squibb Company, H1 2016 24 Lupus Nephritis - Pipeline by Deltanoid Pharmaceuticals Inc., H1 2016 25 Lupus Nephritis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 26 Lupus Nephritis - Pipeline by FibroStatin SL, H1 2016 27 Lupus Nephritis - Pipeline by GlaxoSmithKline Plc, H1 2016 28 Lupus Nephritis - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 29 Lupus Nephritis - Pipeline by Invion Limited, H1 2016 30 Lupus Nephritis - Pipeline by Kineta, Inc., H1 2016 31 Lupus Nephritis - Pipeline by MedImmune, LLC, H1 2016 32 Lupus Nephritis - Pipeline by Omeros Corporation, H1 2016 33 Lupus Nephritis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 34 Lupus Nephritis - Pipeline by Zyrnat Biotherapeutics SL, H1 2016 35 Assessment by Monotherapy Products, H1 2016 36 Number of Products by Stage and Target, H1 2016 38 Number of Products by Stage and Mechanism of Action, H1 2016 40 Number of Products by Stage and Route of Administration, H1 2016 42 Number of Products by Stage and Molecule Type, H1 2016 44 Lupus Nephritis Therapeutics - Recent Pipeline Updates, H1 2016 90 Lupus Nephritis - Dormant Projects, H1 2016 124 Lupus Nephritis - Dormant Projects (Contd..1), H1 2016 125 Lupus Nephritis - Discontinued Products, H1 2016 126
List of Figures
Number of Products under Development for Lupus Nephritis, H1 2016 10 Number of Products under Development for Lupus Nephritis - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Assessment by Monotherapy Products, H1 2016 36 Number of Products by Top 10 Targets, H1 2016 37 Number of Products by Stage and Top 10 Targets, H1 2016 37 Number of Products by Top 10 Mechanism of Actions, H1 2016 39 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 39 Number of Products by Routes of Administration, H1 2016 41 Number of Products by Stage and Routes of Administration, H1 2016 41 Number of Products by Molecule Types, H1 2016 43 Number of Products by Stage and Top 10 Molecule Types, H1 2016 43
Global Bio polyethylene terephthalate (PET) market size is likely to be valued at USD 12.6 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing preference of biopolymers in numerous applications coupled with favorable goverRead More...
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.